A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59

NCT00000632 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
HIV Seronegativity

Interventions

BIOLOGICAL: Env 2-3

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]